Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.38 |
| ▸ | IDH1 | O75874 | 4/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176672 | 0.83 | L3MBTL1 (0.37) | KDM4ELMNASCN9AIDH1PRMT6 | |
| SCHEMBL6176976 | 0.82 | PRMT6 (0.34) | KDM4ELMNASCN9AIDH1LOXL2 | |
| SCHEMBL8125644 | 0.81 | LMNA (0.41) | KDM4ELMNALOXL2HTT | |
| SCHEMBL8126321 | 0.74 | GRM5 (0.43) | KDM4ELMNALOXL2HTT | |
| SCHEMBL6181367 | 0.74 | PRMT6 (0.38) | SCN9AIDH1PRMT6NPC1 | |
| SCHEMBL8120633 | 0.73 | KDM4E (0.39) | KDM4ELMNASLC6A4 | |
| SCHEMBL8119160 | 0.72 | GRM5 (0.38) | KDM4ELMNA | |
| SCHEMBL8119370 | 0.72 | KDM4E (0.36) | KDM4ELMNANPC1RAB9A | |
| SCHEMBL8119910 | 0.71 | LMNA (0.36) | KDM4ELMNASCN9ANPSR1 | |
| SCHEMBL6178955 | 0.70 | PRMT6 (0.34) | SCN9AIDH1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427725-B1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040235667-A1 | Pyrazolyl-substituted thienyloxypyridines | BASF AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1463735-A1 | IMIDAZO[2,1-B]-1,3,4-THIADIAZOLE SULFONAMIDES | Aegera Therapeutics Inc. (CA) | 2004-10-06 | — | — | EP | disclosed |
| EP-1427725-A1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003051890-A1 | IMIDAZO [2,1-B]-1,3,4-THIADIAZOLE SUFLONAMIDES | AEGERA THERAPEUTICS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003022843-A1 | PYRAZOLYL-SUBSTITUTED THIENYLOXYPYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235667-A1 | Pyrazolyl-substituted thienyloxypyridines | HDHD5, CBR3, KCNH3 | KDM4E 3662/4885LMNA 4455/4885SCN9A 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.